Netta BlondheimShraga - Brainstorm Cell Senior Development
| BCLI Stock | USD 1.74 0.12 7.41% |
Executive
Netta BlondheimShraga is Senior Development of Brainstorm Cell Therapeutics
| Address | 1325 Avenue of Americas, New York, NY, United States, 10019 |
| Phone | 201 488 0460 |
| Web | https://www.brainstorm-cell.com |
Brainstorm Cell Management Efficiency
The company has return on total asset (ROA) of (1.782) % which means that it has lost $1.782 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.219) %, meaning that it created substantial loss on money invested by shareholders. Brainstorm Cell's management efficiency ratios could be used to measure how well Brainstorm Cell manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Brainstorm Cell's Return On Capital Employed is increasing as compared to previous years. The Brainstorm Cell's current Return On Equity is estimated to increase to 3.72, while Return On Tangible Assets are projected to decrease to (4.29). The current Total Assets is estimated to decrease to about 4 M. The current Non Current Assets Total is estimated to decrease to about 1.6 MSimilar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matteo MD | Cue Biopharma | 55 | |
| Danine Summers | Trevi Therapeutics | 66 | |
| Gerhard Frey | Bioatla | N/A | |
| JD Esq | Passage Bio | 60 | |
| Katie McManus | Trevi Therapeutics | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Karl Whitney | Passage Bio | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Christian CPA | Bioatla | 48 | |
| Brent Eilefson | Celcuity LLC | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| Jolie JD | C4 Therapeutics | 47 | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| Sheri Lydick | Bioatla | N/A | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Monica Sullivan | Bioatla | N/A | |
| Mark Mossler | C4 Therapeutics | 51 | |
| Kendra Adams | C4 Therapeutics | N/A | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Leonard MD | C4 Therapeutics | 62 | |
Management Performance
| Return On Equity | -11.22 | ||||
| Return On Asset | -1.78 |
Brainstorm Cell Ther Leadership Team
Elected by the shareholders, the Brainstorm Cell's board of directors comprises two types of representatives: Brainstorm Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainstorm. The board's role is to monitor Brainstorm Cell's management team and ensure that shareholders' interests are well served. Brainstorm Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainstorm Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antal PearlLendner, VP Counsel | ||
| Daniel Offen, Chief Advisor | ||
| Ibrahim MD, Executive Officer | ||
| Mary Turner, Senior Affairs | ||
| Hartoun Hartounian, Executive COO | ||
| Netta BlondheimShraga, Senior Development | ||
| Stacy Lindborg, CoChief Officer | ||
| Ralph Kern, COO and Chief Medical Officer | ||
| Chaim Lebovits, President CoCEO | ||
| PharmD MBA, Ex COO | ||
| Yael Gothelf, Vice Affairs | ||
| Irit DSc, CoFounder Board | ||
| William White, Senior Pricing | ||
| Uri Yablonka, COO and Director |
Brainstorm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainstorm Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.22 | ||||
| Return On Asset | -1.78 | ||||
| Current Valuation | 10.6 M | ||||
| Shares Outstanding | 5.7 M | ||||
| Shares Owned By Insiders | 9.00 % | ||||
| Shares Owned By Institutions | 13.89 % | ||||
| Number Of Shares Shorted | 173.85 K | ||||
| Price To Earning | (16.00) X | ||||
| Price To Book | 65.82 X | ||||
| EBITDA | (16.93 M) |
Currently Active Assets on Macroaxis
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.45) | Return On Assets (1.78) | Return On Equity (11.22) |
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.